Unleashing the power of next generation ADC cancer treatments

View Pipeline

Pipeline

AmMax Bio is developing a robust oncology pipeline of Antibody Drug Conjugates (ADCs), with its lead program, AMB-104, incorporating clinically validated components and supported by compelling preclinical data.

AMB
104 VIEW

Latest News

All News

Sep 9, 2026

AmMax Bio Names Suneel K. Gupta, Ph.D. as Chief Scientific Officer to Advance Novel ADC Portfolio
AMB-104, a potential first-in-class ADC to treat AML, expected to enter the clinic in 2027